FDA Clears Breztri for Asthma Use - Top_Thought_Leaders - MDSpire

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

  • By

  • Kathryn Wighton

  • April 28, 2026

  • 2 min

Share

Top Thought Leaders in Pulmonary

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Clears Breztri for Asthma Use

  • by Kathryn Wighton

  • April 28, 2026

Related Content

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

AI Drafts Cut Radiograph Reporting Time

Prospective cohort study found faster documentation, with no statistically significant difference in peer-reviewed report quality

Unburdening healthcare systems through telenursing in chronic respiratory disease management: a systematic review